TISIDB

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	-
Function	Component of the RNF20/40 E3 ubiquitin-protein ligase complex that mediates monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1). H2BK120ub1 gives a specific tag for epigenetic transcriptional activation and is also prerequisite for histone H3 'Lys-4' and 'Lys-79' methylation (H3K4me and H3K79me, respectively). It thereby plays a central role inb histone code and gene regulation. The RNF20/40 complex forms a H2B ubiquitin ligase complex in cooperation with the E2 enzyme UBE2A or UBE2B; reports about the cooperation with UBE2E1/UBCH are contradictory. Required for transcriptional activation of Hox genes. Recruited to the MDM2 promoter, probably by being recruited by p53/TP53, and thereby acts as a transcriptional coactivator. Mediates the polyubiquitination of isoform 2 of PA2G4 in cancer cells leading to its proteasome-mediated degradation.

> Gene Ontology [ TOP ]
Biological Process	GO:0000209 protein polyubiquitination GO:0006378 mRNA polyadenylation GO:0006397 mRNA processing GO:0006479 protein methylation GO:0006513 protein monoubiquitination GO:0008213 protein alkylation GO:0010390 histone monoubiquitination GO:0016570 histone modification GO:0016571 histone methylation GO:0016574 histone ubiquitination GO:0030336 negative regulation of cell migration GO:0031056 regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031060 regulation of histone methylation GO:0031062 positive regulation of histone methylation GO:0031123 RNA 3'-end processing GO:0031124 mRNA 3'-end processing GO:0031396 regulation of protein ubiquitination GO:0031398 positive regulation of protein ubiquitination GO:0031440 regulation of mRNA 3'-end processing GO:0031441 negative regulation of mRNA 3'-end processing GO:0032259 methylation GO:0033182 regulation of histone ubiquitination GO:0033184 positive regulation of histone ubiquitination GO:0033523 histone H2B ubiquitination GO:0040013 negative regulation of locomotion GO:0043414 macromolecule methylation GO:0043631 RNA polyadenylation GO:0050684 regulation of mRNA processing GO:0050686 negative regulation of mRNA processing GO:0051271 negative regulation of cellular component movement GO:1900363 regulation of mRNA polyadenylation GO:1900364 negative regulation of mRNA polyadenylation GO:1902275 regulation of chromatin organization GO:1903311 regulation of mRNA metabolic process GO:1903312 negative regulation of mRNA metabolic process GO:1903320 regulation of protein modification by small protein conjugation or removal GO:1903322 positive regulation of protein modification by small protein conjugation or removal GO:1905269 positive regulation of chromatin organization GO:2000146 negative regulation of cell motility GO:2001166 regulation of histone H2B ubiquitination GO:2001168 positive regulation of histone H2B ubiquitination
Molecular Function	GO:0002039 p53 binding GO:0003682 chromatin binding GO:0003713 transcription coactivator activity GO:0003729 mRNA binding GO:0003730 mRNA 3'-UTR binding GO:0004842 ubiquitin-protein transferase activity GO:0016874 ligase activity GO:0019787 ubiquitin-like protein transferase activity GO:0031625 ubiquitin protein ligase binding GO:0042393 histone binding GO:0044389 ubiquitin-like protein ligase binding
Cellular Component	GO:0000151 ubiquitin ligase complex GO:0000785 chromatin GO:0000792 heterochromatin GO:0031371 ubiquitin conjugating enzyme complex GO:0033503 HULC complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-8866654: E3 ubiquitin ligases ubiquitinate target proteins R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification R-HSA-8852135: Protein ubiquitination

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between RNF20 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of RNF20 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.58	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of RNF20 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.037	0.853
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.146	0.933
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.179	0.898
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.235	0.281
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.404	0.828
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.021	0.993
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.208	0.552
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.116	0.946
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.349	0.85
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.38	0.775
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.929	0.631
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.085	0.105

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of RNF20 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	14.3	10.7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNF20. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNF20. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNF20. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNF20. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of RNF20 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between RNF20 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	RNF20
Name	ring finger protein 20, E3 ubiquitin protein ligase
Aliases	FLJ20382; FLJ11189; KAIA2779; BRE1A; hBRE1; BRE1; BRE1 E3 ubiquitin ligase homolog (S. cerevisiae); ring fin ......
Chromosomal Location	9q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting RNF20 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse RNF20